Dowdy et al. (Dowdy et al., 2020) demonstrated that in IDH-mutant glioma subtypes, the combination of SPHK1 inhibitor N,N-dimethylsphingosine with C17 sphingosine reduced S1P production and enhanced ceramide and sphingosine accumulation. Here, SPHK1 is linked to central nervous system cancer.